Evaluating breath methane as a diagnostic test for constipation-predominant IBS

Digestive Diseases and Sciences

Volumn 55, Issue 2, 2010, Pages 398-403

  Hwang, Laura ^a   Low, Kimberly ^a   Khoshini, Reza ^a   Melmed, Gil ^a   Sahakian, Ara ^a   Makhani, Marc ^a   Pokkunuri, Venkata ^a   Pimentel, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Breath testing; Constipation predominant IBS; Irritable bowel syndrome; Methane

Indexed keywords

LACTULOSE; METHANE;

ADULT; ARTICLE; BLOATING; BREATH ANALYSIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIAGNOSTIC TEST; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; HOSPITALIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; BREATH TESTS; CONSTIPATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; METHANE; MIDDLE AGED; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 76849097800     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0778-4     Document Type: Article

References (31)

1. G Bommelaer T Poynard C Le Pen AF Gaudin F Maurel G Priol, et al. 2004 Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria Gastroenterol Clin Biol 28 554 561 10.1016/S0399-8320(04)95011-7 15243388 PMID: 15243388
2. S Wilson L Roberts A Roalfe P Bridge S Singh 2004 Prevalence of irritable bowel syndrome: a community survey Br J Gen Pract 54 495 502 15239910 PMID: 15239910
3. KA Gwee S Wee ML Wong DJ Png 2004 The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community Am J Gastroenterol 99 924 931 10.1111/j.1572-0241.2004.04161.x 10.1111/j.1572-0241.2004.04161.x 15128362 PMID: 15128362 (Pubitemid 39090225)
4. HB El-Serag 2003 Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life Rev Gastroenterol Disord 3 Suppl 2 S3 S11 12775997 PMID: 12775997
5. AP Hungin PJ Whorwell J Tack F Mearin 2003 The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects Aliment Pharmacol Ther 17 643 650 10.1046/j.1365-2036.2003.01456.x 10.1046/j.1365-2036.2003.01456.x 1:STN:280:DC%2BD3s7islCntg%3D%3D 12641512 PMID: 12641512 (Pubitemid 36418887)
6. L Agreus K Svardsudd O Nyren G Tibblin 1995 Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time Gastroenterology 109 671 680 10.1016/0016-5085(95)90373-9 10.1016/0016-5085(95) 90373-9 1:STN:280:DyaK2MzosF2hsQ%3D%3D 7657095 PMID: 7657095
7. Drossman DA, Richter JE, Talley NJ, et al., eds. Functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus. Boston: Little, Brown; 1994.
8. WG Thompson GF Longstreth DA Drossman, et al. 1999 Functional bowel disorders and functional abdominal pain Gut 45 II43 II47 10457044
9. Rome Foundation 2006 Guidelines-Rome III diagnostic criteria for functional gastrointestinal disorders J Gastrointestin Liver Dis 15 301 312
10. SA Muller-Lissner I Fumagalli KD Bardhan, et al. 2001 Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation Aliment Pharmacol Ther 15 1655 1666 10.1046/j.1365-2036.2001.01094.x 10.1046/j.1365-2036.2001.01094.x 1:CAS:528:DC%2BD3MXnvVCgsL4%3D 11564007 (Pubitemid 32912410)
11. J Novick P Miner R Krause, et al. 2002 A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation Aliment Pharmacol Ther 16 1877 1888 10.1046/j.1365-2036.2002.01372.x 10.1046/j.1365-2036.2002.01372.x 1:CAS:528:DC%2BD38XptFSqtbw%3D 12390096
12. M Camilleri EA Mayer DA Drossman, et al. 1999 Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist Aliment Pharmacol Ther 13 1149 1159 10.1046/j.1365-2036. 1999.00610.x 10.1046/j.1365-2036.1999.00610.x 1:CAS:528:DyaK1MXmvVWhuro%3D 10468696 (Pubitemid 29445893)
13. KD Bardhan G Bodemar H Geldof, et al. 2000 A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome Aliment Pharmacol Ther 14 23 34 10.1046/j.1365-2036.2000.00684.x 10.1046/j.1365-2036.2000.00684.x 1:CAS:528:DC%2BD3cXhtFSisrg%3D 10632642
14. DA Drossman BB Toner WE Whitehead, et al. 2003 Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders Gastroenterology 125 1 19 31 10.1016/S0016-5085(03) 00669-3 10.1016/S0016-5085(03)00669-3 12851867 (Pubitemid 36799103)
15. M Pimentel EJ Chow HC Lin 2000 Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome Am J Gastroenterol 95 3503 3506 10.1111/j.1572-0241.2000.03368.x 10.1111/j.1572-0241.2000.03368.x 1:STN:280:DC%2BD3M%2FpvFSmtA%3D%3D 11151884
16. G Nucera M Gabrielli A Lupascu, et al. 2005 Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth Aliment Pharmacol Ther 21 1391 1395 10.1111/j.1365-2036.2005.02493.x 10.1111/j.1365-2036.2005.02493.x 1:STN:280:DC%2BD2M3oslagsQ%3D%3D 15932370 (Pubitemid 40813686)
17. M Majewski RW McCallum 2007 Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial Adv Med Sci 52 139 142 1:STN:280: DC%2BD1c%2FmsVOitQ%3D%3D 18217406
18. A Lupascu M Gabrielli EC Lauritano, et al. 2005 Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome Aliment Pharmacol Ther 22 1157 1160 10.1111/j.1365-2036.2005.02690.x 10.1111/j.1365-2036.2005.02690.x 1:STN:280:DC%2BD2MnisVKntA%3D%3D 16305730 (Pubitemid 41779524)
19. I Posserud PO Stotzer ES Björnsson, et al. 2007 Small intestinal bacterial overgrowth in patients with irritable bowel syndrome Gut 56 802 808 10.1136/gut.2006.108712 10.1136/gut.2006.108712 17148502 (Pubitemid 46854194)
20. M Pimentel EJ Chow HC Lin 2003 Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study Am J Gastroenterol 98 412 419 12591062
21. A Sharara E Aoun H Abdul-Baki R Mounzer S Sidani I ElHajj 2006 A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence Am J Gastroenterol 101 326 333 10.1111/j.1572-0241.2006.00458.x 10.1111/j.1572-0241.2006.00458.x 1:CAS:528:DC%2BD28XitFSgtro%3D 16454838 (Pubitemid 43381675)
22. M Pimentel S Park J Mirocha S Kane Y Kong 2006 The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome Ann Intern Med 145 8 557 563 17043337
23. A Lembo SF Zakko NL Ferreira, et al. 2008 Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short-term treatment leading to long-term sustained response Gastroenterology 134 A545 10.1016/S0016-5085(08) 62544-5
24. JR Bratten J Spanier MP Jones 2008 Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls Am J Gastroenterol 103 958 963 10.1111/j.1572-0241.2008.01785.x 10.1111/j.1572-0241. 2008.01785.x 1:CAS:528:DC%2BD1cXls1Cqsbo%3D 18371134
25. M Pimentel AG Mayer S Park, et al. 2003 Methane production during lactulose breath test is associated with gastrointestinal disease presentation Dig Dis Sci 48 86 92 10.1023/A:1021738515885 10.1023/A:1021738515885 12645795 (Pubitemid 36232767)
26. M Grover M Kanazawa OS Palsson, et al. 2008 Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress Neurogastroenterol Motil 20 9 998 1008 10.1111/j.1365-2982.2008.01142.x 1:STN:280:DC%2BD1crivFGhtA%3D%3D 18482250
27. M Pimentel HC Lin P Enayati, et al. 2006 Methane, a gas produced by enteric bacteria, slows intestinal transit and augments ileal contractile activity Am J Physiol Gastrointest Liver Physiol 290 G1089 G1095 10.1152/ajpgi.00574.2004 10.1152/ajpgi.00574.2004 1:CAS:528:DC%2BD28XlvVeis7w%3D 16293652 (Pubitemid 43788289)
28. M Pimentel EJ Chow S Park Y Kong 2006 Neomycin improves constipation in IBS in a fashion that is dependent on the presence of methane gas: sub-analysis of a double blind randomized controlled study Dig Dis Sci 51 1297 1301 10.1007/s10620-006-9104-6 10.1007/s10620-006-9104-6 1:CAS:528: DC%2BD28Xosleqsrs%3D 16832617 (Pubitemid 44315794)
29. R Khoshini SC Dai S Lezcano M Pimentel 2008 A systematic review of diagnostic tests for small intestinal bacterial overgrowth Dig Dis Sci 53 1443 1454 10.1007/s10620-007-0065-1 10.1007/s10620-007-0065-1 17990113
30. S Chatterjee S Park K Low Y Kong M Pimentel 2007 The degree of breath methane production in IBS correlates with the severity of constipation Am J Gastroenterol 102 837 841 10.1111/j.1572-0241.2007.01072.x 10.1111/j.1572-0241. 2007.01072.x 1:CAS:528:DC%2BD2sXltlOgsLk%3D 17397408 (Pubitemid 46496615)
31. P Schoenfeld 2005 Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work Gastroenterol Clin North Am 34 319 335 10.1016/j.gtc.2005.02.002 10.1016/j.gtc.2005.02.002 15862938 (Pubitemid 40615959)